Furthermore, we conducted some preliminary cytotoxic activity and discovered that RP6306, a specific inhibitor of PKMYT1, exhibited substantial cytotoxic effects against some solid tumor cell lines, hinting that PKMYT1 could potentially serve as a therapeutic target not only for CML, but also for solid tumors. Here, PKMYT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.